Home Energy Physics Nuclear Power Electricity Climate Change Lighting Control Contacts Links


XYLENE POWER LTD.

COVID-19 THERAPY:

This web page has been added to the Xylene Power Ltd. web site as a service to medical professionals around the world. The information contained herein is believed to be reliable.
 

COVID-19 PRESENTATION:
COVID-19 is a highly contageous novel viral infection that typically presents as some combination of: no obvious symptoms, intermittent headache and fever, exhaustion, a runny nose, a cough, loss of sense of smell, loss of sense of taste, shortness of breath, hypoxia and then death. In about 80% of the COVID-19 cases confirmed by laboratory testing the lungs, heart and the brain are not seriously inflammed and patients seem to recover on their own about three weeks after initial symptoms with little or no medical intervention. However, shortness of breath is an indication of a much more serious COVID-19 case due to lung inflammation. In some cases there may be cardiac damage or neurological damage due to inflammation but this issue is not well documented.

Recent data relating to severe COVID-19 cases indicates wide spread formation of small blood clots.. Treating this clotting problem with blood thinners gives uncertain results.

The frequency of COVID-19 fatalities is much higher among older people with weaker immune systems than among younger people.
 

COVID-19 CONTAINMENT:
It is extremely difficult to contain a COVID-19 outbreak due to an incubation period of up to 14 days, presymptomatic transmission, post symptomatic transmission for about one week, asymptomatic transmission and absence of a proven vaccine. Until there is a COVID-19 vaccine the only certain method of preventing COVID-19 transmission is sustained physical separation of all people and a high degree of hand and other hygiene. The COVID-19 virus is primarily transmitted through air via expelled moisture droplets and survives for 24 to 72 hours on various room temperature surfaces. A temperature of 70 degrees C (160 degrees F) sustained for one half hour is sufficient to disinfect a solid surface.
 

PUBLIC GUIDANCE:
The video titled: Professor Separates Coronavirus Fact From Fiction summarizes the measures necessary to minimize the impact of COVID-19 infections on the public health system.
 

COVID-19 MEDICAL TREATMENT
Generally shortness of breath is addressed by having the patient breath air enriched in O2 while the patient's own immune system combats the disease. However, in the most serious 5% of the laboratory confirmed COVID-19 cases the patient becomes hypoxic in spite of breathing pure O2. At that point the patient is at severe risk of imminent death.

Typically a hypoxic patient is connected to a ventilator, but only about 30% of ventilator connected patients survive. The optimum pressure setting for COVID-19 ventilation is controversial. It appears that often the optimum ventilator pressure setting is significantly less than for common viral pneumonia. Too high a ventilator pressure setting will cause further damage the patient's lungs. The patient's lung mechanical behavior and gas exchange with COVID-19 is complex as further described in videos linked to this web page.
 

COVID-19 LUNG INFLAMMATION:
The main cause of fatalities in COVID-19 patients is serious lung inflammation. Lung inflammation reduces the exchange of gas molecules between the air in the patient's lungs and the patient's blood stream. Hence the primary objective of a COVID-19 therapy is rapid suppression of lung inflammation while providing the patient air enriched in O2.
 

KOREAN EXPERIENCE:
In the following video Dr. Kim Woo-Ju, Professor of Infectious Disease, Guro Hospital, College of Medicine, Korea University, South Korea discusses the South Korean experience with COVID-19. An important lesson from South Korea that politicans elsewhere failed to heed, is the large amount of COVID-19 asymptomatic transmission. One asympotomatic individual can unknowingly infect dozens of other people.

CAUTION: This author believes that South Korea is culturally a more disciplined society than North America in the sense that young people are generally more obedient of their elders. That cultural difference may have contributed to Korea's relative success in suppressing COVID-19.

Dr. Kim Woo-Ju video

Dr. Woo-Ju has researched infectious disease since 1990:
Tuberculosis
Aids
2019 - Swine flu
2013-SARS
2014-Ebola
2015-MERS

Dr. Kim Woo-Ju Video Outline
1:39 ~ "Covid-19 is the most challenging"

2:25 ~ Covid-19 originated in Wuhan, China

2:48 ~ Chinese government notified the World Health Organization (WHO) on 12/31/2019

2:59 ~ Originated from bats, transferred to intermediate hosts including Pangolins and/or snakes

3:45 ~ Concerns raised for all major cities including NYC

4:40 ~ Korean Statistics (3/24/2020)
Reported cases: 8961
Deaths: 111
Asymptomatic: 20%

Korean COVID-19 mortality ages:
80+: 11.6%
70-80: 6.3%
60-70: 1.5%
50-60: 0.4%
40-50: 0.1%
30-40: 0.1%

90% of fatalities are from persons 60 years of age or older.

6:00 Why older persons are so affected

6:43 20% are completely asymptomatic and spread the disease

6:49 Persons over 60 have immune system deterioration (immunosenescence)

7:28 Chronic medical conditions at risk
Smokers
Cardiovascular
Lung disease
Diabetes
Steroid use and persons on chemotherapy

8:08 Those who are infected can become infected again, "Reactivation cases"

8:48 Three main ways to get infected:
Droplets 5+ micron (within 6' of an infected person)
Surface to hand to eye, nose, or mouth
Aerosols, less than 5 microns through the air

11:31 ~ Aerosol transmission through the air
Droplets less than 5 microns
People talking, singing, shouting, praying
Places of assembly, restaurants, markets, houses of worship, bars, gyms, schools,

12:33 ~ Aerosols are spread through the air greater than six feet and stay suspended greater distances.

13:47 ~ Persons who should be tested: anyone coughing, sneezing, or difficulty breathing

14:10 ~ 30% of those infected lose taste and/or smell for 5-10 days

14:42 ~ COVID-19 test in Korea is free to citizens and has a market cost of $140.

15:50 ~ A mask is effective in preventing infection

16:24 ~ People wearing masks have a significantly lower chance of getting infected than those who don't.

16:35 ~ Disagrees with U.S. policy and the Surgeon General of discouraging citizens wearing masks.

18:40 ~ The reason why the transmission rate in Korea was so low was that everyone was wearing masks and washing hands.

18:58 ~ Korea was/is doing 15,000 tests/day, totaling 338,000 tests (3/23/2020)

19:24 ~ Korea was prepared due to the 2009 Swine Flu pandemic and the 2015 MERS outbreak.

21:38 ~ The previous Korean experience with pandemics "was a valuable lesson for us."

23:50 ~ Korean quarantine steps described

27:17 ~ 30% of cases are young adults 20-40 due to less social distancing

27:25 ~ How long will COVID-19 last

27:47 ~ "It won't be over quickly"

27:56 Best Case scenarios
End by July or August
It will return to the northern hemisphere next winter "like seasonal flu"

30:54 ~ It will take a minimum of 18 months to develop a vaccine

31:50 ~ Drug repurposing for treatment of COVID-19

34:00 ~ Concern for welfare of medical personnel

35:00 ~ Advice for young adults
 

SOUTH AFRICAN EXPERIENCE:
Relative to its population, up to April 13, 2020 the number of COVID-19 cases in South Africa was tiny (2000 cases out of a population of 60,000,000). Is this relatively small number of cases attributable to extensive contact tracing, is there something unique about South Africa or is this the calm before the storm? Some people are convinced that the TB Vaccine in use in South Africa enhances natural resistance to COVID-19.
 

NEW YORK CITY INITIAL EXPERIENCE:
Dr. David Price, a doctor on the New York City COVID-19 front line, talks about his practical experience with COVID-19, how to prevent COVID-19 transmission and the circumstances when it is necessary for a patient to seek hospital care.
 

COVID-19 VIRUS SURVIVAL TIME AT ROOM TEMPERATURE ON VARIOUS SURFACES:
Coronavirus Survival Time On Various Surfaces
 

PROFESSIONAL GUIDANCE:
The balance of the information on this web page is intended for front line medical professionals who are facing overwhelming of existing health care resources.
 

FACE MASK GUIDE:
Face Mask Guide
 

HOW TO MAKE A SOPHISTICATED FACE MASK:
Face mask made using vacuum cleaner bag HEPA filter material. This mask should only be used in a COVID-19 environment if approved N95 masks are not available. A better material than the pipe cleaner suggested in the video for making the mask's adjustable nose fitting is the flexible reclosure fastener attached to some commercial 300 g packages of cookies.
 

INAPPROPRIATE AND DANGEROUS VENTILATOR PRESSURE SETTINGS:
A Warning Regarding Inappropriate and Dangerous Ventilator Pressure Settings A US medical doctor alerts other medical professionals that COVID-19 causes lung behavior that is quite different from common viral pneumonia.

NYC Doctor Says Coronavirus Ventilator Pressure Settings Are Too High

A detailed description of the hypoxia and related phenomena observed in COVID-19 patients.

Formal discussion of the COVID-19 lung and hypoxia treatment issues

Doctors Say Ventilators Overused For COVID-19
 

HOW DOES COVID-19 KILL?:
How Does COVID-19 Kill?

How Does Corona Virus Kill?
 

PLAN FOR COVID-19 THERAPY AND VACCINE DEVELOPMENT:
Science Based Plan for Stopping COVID-19
 

COVID-19 THERAPY ISSUES:
This author cautions that the therapies set out below are unproven with COVID-19, may be unsuitable for some patients in some situations and might have undesirable and/or dangerous side effects.

These therapies have been experimentally demonstrated in limited medical settings but have not been subject to large scale double blind clinical testing with COVID-19 infected patients. An ethical problem with double blind testing of a life saving therapy is the reality that patients who do not receive the life saving therapy will likely die.
 

X-RAY THERAPY:
Before the 1960s, X-ray therapies were widely used against many diseases, including different types of infections. When the proper technique (dose, zone and exposure time) was used, the successful cure rate for inflammatory diseases was quite high, ranging from about 75% to 90%. The benefits usually appeared within a day or two. There were few, if any, harmful side effects. This type of treatment induced anti-inflammatory agents in the body, and it stimulated the patient's own natural protection systems. There were no reports of increased cancer incidence or any other long-term effects. The development of antibiotics and other pharmaceutical remedies resulted in the replacement of X-ray therapies by the new drugs that were more convenient to administer.

There is a political barrier to using a low dose of X-rays to reduce lung inflammation, and today we are paying an enormous price for this political problem. Page 5 of Application of Low Doses of Ionizing Radiation in Medical Therapies is as follows:

Present-Day Physicians Avoid Treatments With Low Doses of Radiation
Treatments with LDIR (Low Dose Ionizing Radiation) became very controversial after the 1956 NAS (National Academy of Sciences) recommendation was issued. Physicians began prescribing antibiotics and chemical treatments instead of treatments with low doses of radiation. For many decades, radiologists have been carefully taught the LNT (Linear No Threshold) ideology that any exposure to IR (Ionizing Radiation) carries a risk of cancer. They are constantly urged to avoid any use of such radiations and to minimize the dose of diagnostic X-rays and computed tomography (CT) scans. The potential benefit of any procedure that uses IR is to be weighed against the risk of cancer, as calculated by the LNT model. It appears to be unacceptable for physicians to learn about or use LDIR therapy. Medical textbooks fail to mention an important characteristic of the normal aerobic metabolism, namely that the mitochondria leak ROS (Reactive Oxygen Species), which cause endogenous damage to DNA and other biomolecules at a very high rate. Pollycove and Feinendegen have pointed out that very powerful adaptive protection systems have evolved, which act against this high rate of DNA and other biomolecular damage. Physicians are not taught the experience of the past 120 years that low doses of radiation stimulate the protection systems, including the immune system, which involve more than 150 genes. They do not learn about the biphasic dose–response model (Figure 2) and are unaware of dose thresholds for the onset of radiogenic cancer. Without an informed medical community, it is impossible for researchers to initiate clinical studies of LDIR therapies that would stimulate a patient’s protection systems. When conventional treatments fail to remedy a patient’s life-threatening disease and an LDIR therapy is provided as a last resort, a case report may be issued that describes the significant benefits observed.

Since 1995, Dr. Jerry Cuttler (jerrycuttler@rogers.com, Cell 1 416 837 8865) has been collaborating with renowned medical scientists and radiobiologists to understand the health effects of radiation. He recently participated in a small clinical trial in Toronto on an X-ray therapy for Alzheimer's disease. When the COVID-19 epidemic appeared in the U.S. and Canada, he proposed to the US FDA (Food and Drug Administration) and to Sunnybrook Hospital that patients with severe chest inflammation be given X-ray therapy, as was successfully employed to treat patients with pneumonia inflammation in the first half of the 20th century. Sunnybrook is examining this potential remedy.

On March 26, 2020 Dr. Jerry Cuttler recommended an X-ray dose to the lungs of 0.5 Gy (i.e., 50 cGy) as a treatment for lung inflammation arising from COVID-19. He anticipates obvious benefits of the treatment within two hours to two days.

Jerry Cuttler was asked:"In terms of suppression of COVID-19 lung inflammation is there any practical difference between a 0.5 Gy chest X-ray dose and a whole body 0.5 Gy X-ray dose?"

Jerry Cuttler's response was as follows:"Yes there is a very important difference. The blood-forming stem cells in bone marrow are more radiation-sensitive than any of the other cells. Dr. Sakamoto observed (not very severe) lymphocytopenia (a lowering of the lymphocyte count in the bloodstream) in some of his (cancer) patients when he gave multiple, whole-body doses of 0.1 or 0.15 Gy to a total of 1.5 Gy, over a 5 week period."

"Lymphocytes are part of the immune system, which the patient badly needs to recover from the COVID-19 infection. So the 0.5 Gy exposure should be limited to lung area, to remedy the lung inflammation without severely damaging the patient’s immune system."

"I think an X-ray machine that can deliver 100 kV X-rays with a beam current of about 100 mA can deliver a lung dose of 50 rad or 0.5 Gy within one minute, with the patient about 1 metre from the X-ray tube." The patient dose has to be measured by a RT (Radiation Therapy) physicist.

Jerry Cuttler says:
Rather than pump oxygen into the lungs, the doctors need to remediate the inflammation. The inflammation creates a thick barrier between the air/oxygen molecules and the blood vessels that need to absorb the O2.

The 0.5 Gy X-ray dose induces an "anti-inflammatory phenotype" that quickly resolves the inflammation. (The radiation works on the immune system that caused the inflammation.)

Dr. Jerry Cuttler says that the effect of the radiation therapy is to quickly reduce lung inflammation so that the patient does not sufficate before his/her immune response can suppress the COVID-19. The Wiki explanation for the cellular response is as follows:

"One of these functions is immune-mediated cell death, and it is carried out by T cells in several ways: CD8+ T cells, also known as "killer cells", are cytotoxic - this means that they are able to directly kill virus-infected cells as well as cancer cells. CD8+ T cells are also able to utilize small signalling proteins, known as cytokines, to recruit other cells when mounting an immune response. A different population of T cells, the CD4+ T cells, function as "helper cells". Unlike CD8+ killer T cells, these CD4+ helper T cells function by indirectly killing cells identified as foreign: they determine if and how other parts of the immune system respond to a specific, perceived threat."

It takes time, 1 to 2 weeks, for T cells to learn to recognize virus-infected cells and then build an army to go after them.
 

MAY 10, 2020 Email:
On May 10, 2020 Dr. Jerry Cutler sent the following explanatory email to a group of associates:
Cancer cells are different than normal cells. Cancer cells are mutated; they do not have the all the protection systems of normal cells. So when a mutated or cancer cell is sprayed with liquid nitrogen (LN) or zapped with sufficient ionizing radiation, that cell dies. However, a healthy cell can repair the damage and recover from the LN or the radiation exposure.

The usual radiation treatment for a cancer tumor is 2 Gy per day for 5 weeks. The total dose is 2 Gy x 5 x 5 = 50 Gy. After each 2 Gy dose fraction, the health cells recover, but the cancer cells deteriorate. After 25 exposures the cancer cells are usually dead and have been removed.

When we talk about COVID-19 disease, we talk about virus-infected human cells. Virus-infected cells are destroyed by our adaptive immune system. This system requires at least one week to produce specific antibodies that will selectively identify all the SARS-CoV-2 virus-infected cells for destruction by the customized killer T cells.

Those COVID-19 patients, who have a strong innate immune system reaction to the infection, develop severe lung inflammation. Their lungs fill up with fluids and debris, which blocks the transfer of oxygen to their blood. A supply of O2 and a ventilator in the ICU are usually not enough to remedy the acute respiratory distress syndrome (ARDS), and most of these patients die from suffocation.

From the 1930s to the 1940s, many patients with severe pneumonia were given a low dose of radiation (LDR) of 0.5 Gy to the lungs. This exposure produced an anti-inflammatory phenotype that decreased the lung inflammation and allowed the patient to breathe. Patients with viral pneumonia recovered after one or two weeks. Their adaptive immune system destroyed all of the virus-infected cells. The clinical trials that have just started will determine whether this LDR lung treatment will remedy the SARS-CoV-2 virus-induced lung inflammation.

Note that the 0.5 Gy dose to the lungs is 1% of the total dose employed to remedy lung cancer. The acute lethal dose for virus particles was determined in the 1950s. It ranges from about 100 Gy to about 10,000 Gy.
 

PILOT TRIAL OF LOW DOSE IONIZING RADIATION THERAPY FOR MITIGATING COVID_19
Pilot Low Dose Radiation Therapy Trial at Emory Winship Cancer Institute
 

PILOT TRIAL RESULT:
Date: Mon, Jun 8, 11:52 PM
Emory-Winship pilot trial data now a preprint to access here:
Emory-Winship COVID-19 low dose radiation therapy pilot trial result
 

Conclusions:
In a pilot trial of five oxygen-dependent patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvement in clinical status, encephalopathy, and radiographic infiltrates without acute toxicity. Low-dose whole-lung radiation is safe, shows early promise of efficacy, and warrants further study in larger prospective trials.
 

Dr. Jerry Cuttler is a highly respected 78 year old scientist. At this time he is under considerable stress. Please do not bother him unnecessarily unless his technical expertise is required. However, he is very interested in receiving patient and treatment information and results.

References:
Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today?
Yale J Biol Med. 2013;86:555-570
 
Cuttler JM. Application of low doses of ionizing radiation in medical therapies
Dose Response. 2020;18(1):1-17
 
Email from U.K. Dr. Chris Hamilton indicating his personal and mentor's experience with X-ray Therapy for pneumonia suppression
 
Roentgen Therapy of Virus Pneumonia Oppenheimer - American journal of roentgenology and radium therapy pages 635-638, 1943
 
Letter to Dr. Stephen Hahn of US FDA re: US Clinical Trial of Radiation Therapy
 
SARI Position Statement on the Health Effects of Radiation
 
LDR therapy as a potential life saving treatment for COVID-19
 
A new 4-page justification for a trial of the 0.5Gy LDR treatment for COVID-19, by Rödel et al The mechanism is quite complicated. However, we know that this treatment might work from past experience.
 
US PreVent Trial of Radiation Therapy for Treating COVID-19
 
Investigating Low Dose Thoracic Radiation for COVID-19. Parties that copy this file by any means owe $15.00 per copy to the Radiation Research Society.
 

Experiments Using Dogs:
Evidence That Lifelong Low Dose Rates of Ionizing Radiation Increase Lifespan in Long- and Short-Lived Dogs
 
Evidence of a Dose-Rate Threshold for Life Span Reduction of Dogs Exposed to Gamma Radiation
 

Clinical Trials:
Spanish radiation oncologists endorse Low Dose Radiation therapy for COVID-19 inflammation in English
 
Spanish radiation oncologists endorse Low Dose Radiation therapy for COVID-19 inflammation
 
Low dose chest radiation for COVID-19 patients
 
Pilot Trial in India of Low Dose Radiation therapy for treating COVID-19
 

CHLOROQUINE THERAPY:
Certain cocktails of chloroquine based anti-malarial drugs are alleged to mitigate the effects of COVID-19 in certain situations. Chloroquine family drug therapy is particularly relevant to tropical countries that already possess large stocks of these anti-malarial drugs. The relevant files appear below.

One of the challenges of chloroquine family drug therapy is that the underlying COVID-19 treatment mechanism is not well understood. Different clinical trials by different teams of reputable investigators have yielded wildly different results. It may be that trace molecular concentrations in the drug cocktail are important and have been different in the various clinical trials.

There has also been speculation that some population groups routinely take chloroquine family drugs for other reasons such as lupus and malaria and their prior use of these chloroquine family drugs might confuse the clinical trial results. There is also speculation that the real positive effect of chloroquine drug therapies is to enable supply Zn and/or Se ions to persons whose immune systems are deficient in these ion species, which ions are believed to be essential for strong human immune system response.

It is interesting that the alleged success Dr. Vladimir Zelenkov is having in a NY Orthodox Jewish community treating CV-19 using the triple cocktail of hydroxychloroquine, azithromycin, and zinc sulfate focuses on the key trace element Zn. The Zn is only therapeutically available if the hydroxychloroquine is given to open the cell membranes to let the Zn++ ions into the cell where they are believed to prevent explosive virus replication. If this treatment is in fact working as claimed, with no deaths or hospitalizations, it still does not indicate whether the therapeutic benefit is due to an endemic Zn deficiency in the population treated or if anyone would receive therapeutic benefit from this drug cocktail. Small amounts of Se are also involved in enzymes for the anti-oxidant protective systems and may also be required in a reliable drug therapy.

It appears that on average patient immune resistance to COVID-19 varies inversely with patient age, so there likely is a chemical change to the immune system that progresses with increasing patient age. If the aforementioned theory is correct then the concentrations of the trace elements Zn and Se in the human body might be reliable indicators of a patient's potential susceptibility to serious COVID-19 disease.

Hydrooxychloroquine and azithromycin treatment for COVID-19
and
Chloroquine Therapy
and
These Drugs Are Helping Our Coronavirus Patients

WARNING:
Some chloroquine family chemicals are highly toxic. Chloroquine family drugs are also known to cause heart arhythmia in some people. Chloroquine family drugs interact with the human body in complex ways and should only be used with expert guidance.
 

On March 24, 2020 Joanna Frketich of the Hamilton Spectator newspaper reported on a planned multi-institute clinical trial of chloroquine family drugs led by Dr. Richard Whitlock and Dr. Salim Yusuf of the Population Health Research Institute (PHRI) which is affiliated with McMaster University and Hamilton Health Sciences and by Dr. Emilie Belley-Cote, a Hamilton cardiologist and intensivist. Also on the proposed clinical trial team are Dr. Mark Loeb, division director of infectious diseases at McMaster University; Dr. Dominik Mertz; Dr. John Eikelboom; Dr. Hertzel Gerstein; Dr. Sonia Anand; Dr. Elizabeth Richardson; Dr. Marek Smeija and Dr. Deb Cook.

They are starting with $500,000 drawn from from PHRI but that sum will likely not be sufficient for properly carrying out and reporting on the contemplated clinical trial. They contemplate studing 500 COVID-19 patients in hospital and 1000 COVID-19 patients in the community. Randomly chosen patients would receive the chloroquine family drug treatment and the remainder would not. They anticipate having clinical trial results within a few months.

A March 25, 2020 TV news report indicated the planning of another chloroquine family drug clinical test in the Province of Manitoba, but at this time this author has no further detail.
 

IMMEDIATE CLINICAL TRIAL FUNDING:
An issue of huge concern is immediate clinical trial funding. What is the point of the Canadian government committing $107 billion dollars to temporary interim assistance for workers, businesses and hospitals if the underlying serious problem of pneumonia, which is the main cause of COVID-19 deaths, is not immediately addressed? Development and testing of a COVID-19 vaccine and then subsequent vaccination of the entire population is reasonably projected to take close to two years. Hence obtaining reliable data from clinical trials for the efficacy of X-ray and drug therapies is of the utmost importance.

However, an initial approach to Innovations Canada which highlighted the importance of immediate funding for these clinical trials and related work was rejected out of hand as not being within existing program rules and guidelines. This issue has been raised with MP Scot Davidson (Scot.Davidson.c1@parl.gc.ca) It is our hope that the federal cabinet will direct Innovations Canada to immediately fund clinical trials of interim COVID-19 therapies as a national priority and will further direct Innovations Canada to set aside existing program rules as necessary to enable these clinical trials to proceed forthwith. Every day of delay adds to the COVID-19 patient death count.

A second funding application has been made to the Government of Ontario via MPP Caroline Mulroney (Caroline.Mulroneyco@pc.ola.org).
 

TREATMENT SCALE-UP
Attempts are being made to involve the Bill and Melinda Gates Foundation via CEPI (Coalition for Economic Preparedness Innovations) with respect to large scale use of the aforementioned therapies for combating COVID-19 infections in Africa. It is contemplated that videos detailing important aspects of the X-ray therapy and chloroquine drug therapy will be made for broadcast in multiple languages. In 2013-2014 Julia Rhodes produced educational medical videos relating to major tropical diseases with Gates Foundation and Al Jazeera/Lifelines support. On March 26, 2020 Julia Rhodes advised Charles Rhodes that she still has available to her in South Africa the resources necessary to make educational medical videos.

The limited medical resources in much of rural Canada are analogous to the limited medical resources in much of Africa. A COVID-19 infection treatment that is clinically tested in one place will likely be suitable for use in the other place. As of March 22, 2020 large stocks of chloroquine family anti-malarial drugs were readily available in much of equatorial Africa. However, X-ray equipment that can provide the required controlled X-ray dose is likely more readily available in urban Canada. In remote parts of Canada the problem of total absence of sophisticated medical support is almost insurmountable.
 

PATIENT RECORDS:
For both of the aforementioned therapies it is important to keep good patient records to allow evaluation of treatment efficacy and to prevent the same patient receiving multiple treatments. Over treatment could cause radiation over dose or drug over dose.
 

COVID-19 MORTALITY PROJECTION:
It is time for politicians to face reality. Here is a "back of an envelope" calculation to think about:

Assume that the population of Ontario is 14,400,000.

Assume that 1% of the population of Ontario is in retirement/nursing home care = 144,000
This population is almost all over 80 years old.

Assume that due to large numbers of staff and visitors in close contact with patients it proves to be impossible to stop the propagation of COVID-19 in a retirement/nursing home environment. This assumption is fundamentally different from the assumption by the government of Ontario that, in spite of experimental evidence to the contrary, the government will be able to prevent propagation of COVID-19 in retirement/nursing homes. The fundamental problem is that 3X per day staff changes potentially enable COVID-19 to penetrate an retirement/nursing home. According to the Toronto Star newspaper as of April 3, 2020 there were about 80 known COVID-19 outbreaks in Ontario's 750 retirement/nursing homes. One infected staff member can infect several patients before showing symptoms. The infected patients can then infect both other staff members and other patients before showing symptoms. Even if every staff person is tested every day, keeping COVID-19 out of retirement/nursing homes appears to be an almost insurmountable task. To keep the retirement/nursing home patients safe the staff must live in physical isolation from the rest of society. However, ongoing physical isolation of retirement/nursing home staff from their own families is simply not practical.

Then due to the average age of the retirement/nursing home patient population even with the best medical care eventually 25% will die due to COVID-19 = 36,000 deaths in Ontario

Assume that the retirement/nursing home patient population of Canada is 3X the retirement/nursing home patient population of Ontario = 108,000 COVID-19 retirement/nursing home patient deaths in Canada

Assume that the retirement/nursing home distribution in the USA is similar to the retirement/nursing home distribution in Canada.

Assume that the population of the USA is 10X the population of Canada = 1,080,000 retirement/nursing home COVID-19 deaths in the USA

Assume that about 33% of the total COVID-19 deaths in the USA are unrelated to a retirement home environment = 540,000 non-retirement home deaths in the USA

Hence the projected eventual total number of COVID-19 US deaths = 1,080,000 + 540,000 = 1,620,000 US deaths. As of April 6, 2020 there were already 10,781 known US COVID-19 deaths. This nightmare is already happening.

The recent propaganda from the White House projects 100,000 to 240,000 COVID-19 deaths

There is at least a 6:1 discrepency between the above calculated COVID-19 US mortality projection and the White House projection.

It appears that the practical way to mitigate this carnage is for family members to care for elderly relatives in their own homes while doing all necessary to prevent COVID-19 from entering their own homes. The concept of institutional care of the aged seems to be impractical in the presence of a lethal highly contageous virus that is easily spread by asymptomatic persons. This failure of institutional old age care may have implications on North American family structure for many years to come. We are facing the blunt reality that if an elderly person requires more on-going care than his/her relatives can physically provide, then putting that elderly person permanently to sleep with morphine may be the only viable solution. Even so, it is still necessary to suppress community spread of COVID-19.
 
 


DR. CHARLES RHODES, P.Eng., B.Sc., M.A.Sc., Ph.D.

Canadian Phone: 905 473 1704
 
Email: CSLRhodes@gmail.com
Email: Charles.Rhodes@xylenepower.com

Dr. Charles Rhodes is presently promoting the work of his FOEI (Future of Energy Initiative) colleague Dr. Jerry Cuttler who has done extensive research into use of low dose radiation for improving dog and human life spans.

Charles Rhodes is the Chief Engineer of Xylene Power Ltd. and Micro Fusion International Ltd. Dr. Rhodes has 50 years of physics and engineering experience that includes development, manufacture, installation, operation and maintenance of: distributed energy control and mechanical equipment monitoring systems for major buildings, thermal energy storage systems, pipelines, high efficiency boilers and grid connected behind-the-meter electricity generation systems.

Dr. Rhodes has been an intervenor and expert witness in Ontario Energy Board (OEB) electricity rate hearings. He has also been an expert witness in Alberta Energy Board (AEB) hearings relating to wind generation and buried sour gas pipe lines. He has supported various parties in interventions relating to interprovincial and interstate pipelines.

Other work by Dr. Rhodes has been in the areas of engineering education, engineering management, corporate management, power line carrier, RF, VHF, and UHF communication systems, microcontrollers, microprocessor and microcontroller programming for real time control, electricity and heat metering, electricity rate and regulatory issues, wind generation, fluorescent lighting, solid state device fabrication and characterization, high vacuum systems, cryogenic physics, semi-stable plasmas, structure of atomic particles, nuclear waste disposal, fast fission and fusion reactors, biofuels and the physics of climate change. Much of his recent work has been related to liquid sodium cooled modular fast neutron reactors.

Dr. Rhodes has broad experience that spans almost all aspects of energy.
 
 


 

JULIA RHODES (AKA JULIA SUMMER):

Julia Rhodes, actress, singer, artist, show host, film and web video producer
South Africa Phone: 011 27 72 108 0328
Email: JuliaRhodesactress@gmail.com
 
Websites:
JULIA RHODES FILMOGRAPHY
CHARMING PENGUIN PRODUCTIONS
JULIA RHODES AT MIRAN MEDIA
 

Julia has extensive experience working in Africa on water purification and and on tropical disease issues in conjunction with the Bill and Melinda Gates Foundation and Al Jazeera. As of March 22, 2020 Julia is located in Capetown, South Africa.

EXAMPLES OF JULIA'S RECENT WORK:
2020 Social Media Marketing and Advertising Trends You Need To Know (12 pages)

2019 Radio Advertisement for Coronation Investments

2019 2 U Video Voice Artist

2018 Julia Rhodes Portfolio

2018 Social Algorithms - Win the Platforms By Julia Rhodes

2018 Julia's video promoting career training with Standard Bank

2017 Adidas Influencer Campaign involving famous South African athletes and fitness gurus

2017 Julia's voiceover in a Publix pharmacy advetisement

2017 The Little Vampire 3D - Voiceover - Julia is the blond mother

2016 The Declining Attention Span of Social Media Users and How to Engage Them

2016 Thermo Fisher Scientific PCR Introduction

2016 Future Movers Summit bank training program

2016 Upgrading GE and Maersk websites

2016 Miran Media is an International Content Agency, based in Africa, Asia and Europe.

2015 A beginners guide to social media advertising

2015 Facebook ads 101

2015 Facebook Twitter are adapting to mobile video streaming

2014 Viral video campaign produced by Julia Rhodes (view count over 4 000 000)

During 2013 - 2014 Julia worked with Al Jazeera/Lifelines producing disease control videos for the Bill & Melinda Gates Foundation.
She also had character roles in South Africa produced TV serials such as SAF3.

2013 Al Jazeera anchor Julia Rhodes promoting work of Bill & Melinda Gates Foundation

2012 Julia Rhodes in TV series Supernatural

2012 JiggyTV video demo reel
 
 

XYLENE POWER LTD.
20190 Kennedy Road,
Sharon, Ontario
Canada
L0G 1V0
Attention: Charles Rhodes
 
Phone: 905 473 1704
 
Email: Charles.Rhodes@xylenepower.com
 
 

This web page last updated June 17, 2020.

Home Energy Physics Nuclear Power Electricity Climate Change Lighting Control Contacts Links